Gsk (GSK) Cash from Operations Growth (3y) (2012 - 2026)
Gsk (GSK) Cash from Operations Growth (3y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 27.24% |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | -18.38% |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 13.18% |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 18.04% |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | -0.88% |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 15.19% |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 39.10% |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 42.05% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 73.44% |
| Dec 31, 2025 | 7.57% |
| Mar 31, 2025 | -17.89% |
| Dec 31, 2024 | -25.05% |
| Mar 31, 2024 | -7.88% |
| Dec 31, 2023 | -22.53% |
| Sep 30, 2023 | -15.93% |
| Jun 30, 2023 | -21.85% |
| Mar 31, 2023 | -34.42% |
| Dec 31, 2022 | -3.49% |
| Sep 30, 2022 | -20.33% |
| Jun 30, 2022 | -5.53% |
| Mar 31, 2022 | 50.80% |
| Dec 31, 2021 | 43.51% |
| Sep 30, 2021 | 4.00% |
| Jun 30, 2021 | 7.32% |
| Mar 31, 2021 | 15.03% |
| Dec 31, 2020 | -22.57% |
| Sep 28, 2020 | 23.85% |
| Jun 30, 2020 | 38.57% |